Alnylam Pharma (ALNY) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of $60.07B. The enterprise value is $42.48B.

Alnylam Pharma has 131,079,010 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is -4.15 and return on invested capital (ROIC) is -4.21%.

The current PE Ratio of Alnylam Pharma is ―. Alnylam Pharma’s PEG ratio is ―.

In the last 12 months, Alnylam Pharma had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.

In the last 12 months, operating cash flow was -15.54M and capital expenditures -36.55M, giving a free cash flow of -52.09M billion.

Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Alnylam Pharma upcoming earnings date is Oct 23, 2025, Before Open (Confirmed).

Alnylam Pharma as a current ratio of 2.78, with Debt / Equity ratio of 517.60%

In the past 12 months, Alnylam Pharma has paid -99.22M in taxes.

Alnylam Pharma EV to EBITDA ratio is -169.79, with an EV/FCF ratio of -713.03.

Alnylam Pharma has $2.86B in cash and marketable securities with $1.30B in debt, giving a net cash position of -$1.56B billion.

Gross margin is 83.64%, with operating margin of -7.87%, and net profit margin of -12.37%.

The average price target for Alnylam Pharma is $439.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy